Skip to main content
Hemostemix Inc. logo

Hemostemix Inc. — Investor Relations & Filings

Ticker · HEM ISIN · CA4236943060 LEI · 984500C65BB0B8159L77 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 212 across all filing types
Latest filing 2026-04-09 Proxy Solicitation & In…
Country CA Canada
Listing TSXV HEM

About Hemostemix Inc.

https://hemostemix.com/

Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 80% confidence The document is a formal notice to securities regulators outlining the details of an upcoming Annual General and Special Meeting (record dates, meeting date, format, voting security details). It is part of the proxy solicitation process—providing information to facilitate shareholder voting. There is no financial result, legal proceeding, or report attached, so it fits the Proxy Solicitation & Information Statement category.
2026-04-09 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a formal notice to securities regulators regarding the details of an upcoming Annual General and Special Meeting, including record dates, meeting date, notice and access details, and security information. This aligns with proxy solicitation materials (i.e., the Notice of Meeting) rather than a full report or financial statement. Therefore, the document best fits the Proxy Solicitation & Information Statement category (PSI).
2026-04-09 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 80% confidence The document is a press release announcing Sixty Six Capital’s adoption of semi-annual reporting under a blanket order. It is not itself a financial report nor an AGM/EGM result, dividend, share issue, or earnings release. It constitutes a regulatory announcement of a change in disclosure policy that does not fit a more specific category, making it a general regulatory filing. Therefore, it is classified as RNS (Regulatory Filings).
2026-04-09 English
Notice of the meeting and record date - English.pdf
Capital/Financing Update Classification · 91% confidence The document is a press release announcing an update on Kobo Resources’ non-brokered private placement (financing activity), including extension of closing date, the size and pricing of the offering, use of proceeds, and engagement of an independent firm for a mineral resource estimate. This is an update on company fundraising/financing, matching the Capital/Financing Update category.
2026-04-09 English
Notice.pdf
Audit Report / Information Classification · 95% confidence The document is a formal 'Notice of Change of Auditor' filed by Hemostemix Inc. in accordance with National Instrument 51-102. It details the resignation of a former auditor and the appointment of a successor. Since this is a regulatory disclosure regarding corporate governance and audit oversight that does not fit into specific categories like 'Board/Management Information' (which focuses on personnel) or 'Audit Report' (which is the audit itself), it falls under the general regulatory filing category. FY 2025
2026-02-02 English
Letter from former auditor.pdf
Audit Report / Information Classification · 95% confidence The document is a formal letter from an accounting firm (MNP LLP) to securities commissions regarding a 'Notice of Change of Auditor'. This is a regulatory requirement under National Instrument 51-102. Since it does not fit into specific categories like financial reports, earnings, or shareholder voting, and is a formal regulatory communication regarding auditor status, it falls under the general regulatory filings category. FY 2025
2026-02-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.